ArticleMalaria journal2006
A database of antimalarial drug resistance.
Article in Malaria journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Molecular Surveillance for Imported Antimicrobial Resistant Plasmodium falciparum, Ontario, Canada.Emerging infectious diseases · 2022Article
- Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991-2019.Malaria journal · 2020Article
- KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking.Journal of cheminformatics · 2018Article
- Sharing individual patient and parasite-level data through the WorldWide Antimalarial Resistance Network platform: A qualitative case study.Wellcome open research · 2017Article
- West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia.The American journal of tropical medicine and hygiene · 2016Article
- Review
- Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.The Journal of infectious diseases · 2015Article
- Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal.Malaria journal · 2013Article
- Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds.Open biology · 2013Article
- Functional expression of parasite drug targets and their human orthologs in yeast.PLoS neglected tropical diseases · 2011Article
- Is chloroquine making a comeback?The Journal of infectious diseases · 2011Article
- CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.Malaria journal · 2010Article
- Differentiating Plasmodium falciparum alleles by transforming Cartesian X,Y data to polar coordinates.BMC genetics · 2010Article
- Article
- RNA interference in infectious tropical diseases.The Korean journal of parasitology · 2008Review
- Modeling the inhibition of quadruple mutant Plasmodium falciparum dihydrofolate reductase by pyrimethamine derivatives.Journal of computer-aided molecular design · 2008Article
- Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.Antimicrobial agents and chemotherapy · 2007Article
- A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.Journal of clinical microbiology · 2007Article
- Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project.Malaria journal · 2007Review
- Molecular epidemiology of malaria.Clinical microbiology reviews · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A large investment is required to develop, license and deploy a new antimalarial drug. Too often, that investment has been rapidly devalued by the selection of parasite populations resistant to the drug action. To understand the mechanisms of selection, detailed information on the patterns of drug use in a variety of environments, and the geographic and temporal patterns of resistance is needed. Currently, there is no publically-accessible central database that contains information on the levels of resistance to antimalaria drugs. This paper outlines the resources that are available and the steps that might be taken to create a dynamic, open access database that would include current and historical data on clinical efficacy, in vitro responses and molecular markers related to drug resistance in Plasmodium falciparum and Plasmodium vivax. The goal is to include historical and current data on resistance to commonly used drugs, like chloroquine and sulfadoxine-pyrimethamine, and on the many combinations that are now being tested in different settings. The database will be accessible to all on the Web. The information in such a database will inform optimal utilization of current drugs and sustain the longest possible therapeutic life of newly introduced drugs and combinations. The database will protect the valuable investment represented by the development and deployment of novel therapies for malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.